Metolazone in treatment of severe refractory congestive cardiac failure.

Abstract

17 patients with New York Heart Association (NYHA) class IV congestive cardiac failure, refractory to conventional treatment, were additionally treated with oral metolazone (1.25-10 mg daily). 12 improved sufficiently to be discharged from hospital (NYHA class II or III, mean weight loss 8.3 kg), 1 of whom died at home 4 weeks later. The other 5 patients were treated with intravenous dobutamine for 72 h; 2 responded (average weight loss 4.4 kg), and 2 responded to subsequent reintroduction of metolazone. 4 of these 5 patients died, 2 in hospital of acute myocardial infarction. Overall, 15 patients with very severe refractory cardiac failure improved sufficiently to be discharged from hospital. Treatment was associated with mild transient hypokalaemia in 7 patients, and hyponatraemia and renal impairment in 1, for whom metolazone dosage had to be reduced. Failure to respond to the introduction of metolazone may indicate an especially poor prognosis.

• Authors: A Kiyingi, M J Field, C C Pawsey, J Yiannikas, J R Lawrence, W J Arter
• Journal: Lancet (London, England) (Lancet) Vol. 335 Issue 8680 Pg. 29-31 (Jan 06 1990) ISSN: 0140-6736 [Print] England
• PMID: 1967337 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Diuretics
• Dobutamine
• Metolazone

Topics

• Aged
• Aged, 80 and over
• Body Weight (drug effects)
• Clinical Trials as Topic
• Diuresis (drug effects)
• Diuretics (therapeutic use)
• Dobutamine (administration & dosage, therapeutic use)
• Drug Evaluation
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Heart Failure (drug therapy)
• Humans
• Infusions, Intravenous
• Male
• Metolazone (administration & dosage, adverse effects, therapeutic use)
• Middle Aged
• Prognosis